Drug Trial News

RSS
SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

25 Mar 2011
Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

25 Mar 2011
Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

25 Mar 2011
Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease

Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease

25 Mar 2011
Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

25 Mar 2011
Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

Clinical trial to determine whether Crestor can prevent new colon tumors after surgery

25 Mar 2011
Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

25 Mar 2011
Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

24 Mar 2011
Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

24 Mar 2011
Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

24 Mar 2011
Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

24 Mar 2011
Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

24 Mar 2011
Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

Gilead's elvitegravir Phase III trial against HIV-1 meets primary objective

24 Mar 2011
Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

24 Mar 2011
KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios commences KB004 Phase 1 trial in patients with leukemia

24 Mar 2011
Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

23 Mar 2011
MnSOD oral drug can protect against lung cancer radiation therapy

MnSOD oral drug can protect against lung cancer radiation therapy

23 Mar 2011
Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

23 Mar 2011
Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

23 Mar 2011
ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

23 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback